Business Description
Integra Lifesciences Holdings Corp
NAICS : 339112
SIC : 3841
ISIN : US4579852082
Share Class Description:
IART: Ordinary SharesTotal Employee Number:
4,427Description
Integra Lifesciences Holdings Corp is a New Jersey-based medical equipment company focused on developing products for regenerative therapy, extremity orthopedics, and neurosurgical applications. The firm is organized into two primary segments: Codman specialty surgical and Tissue technologies. Codman Specialty Surgical generates maximum revenue from its segmental operations. Integra serves Europe, Asia Pacific, and the rest of the world whilst it derives key revenue from domestic sales. The company operates in United States, Europe, Asia Pacific, and Rest of the World.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.13 | |||||
Equity-to-Asset | 0.29 | |||||
Debt-to-Equity | 1.96 | |||||
Debt-to-EBITDA | 8.36 | |||||
Interest Coverage | 0.71 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | 1.31 | |||||
Beneish M-Score | -2.69 | |||||
WACC vs ROIC | ||||||
Growth Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 4.6 | |||||
3-Year EPS without NRI Growth Rate | -12.8 | |||||
3-Year Book Growth Rate | -14.7 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 8.27 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 3 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 46.72 | |||||
9-Day RSI | 43.61 | |||||
14-Day RSI | 44.24 | |||||
3-1 Month Momentum % | 1.94 | |||||
6-1 Month Momentum % | 72.28 | |||||
12-1 Month Momentum % | 14.38 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 3.6 | |||||
Quick Ratio | 2.11 | |||||
Cash Ratio | 0.83 | |||||
Days Inventory | 226.9 | |||||
Days Sales Outstanding | 60.13 | |||||
Days Payable | 42.08 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | 2.4 | |||||
Shareholder Yield % | -2.36 |
Profitability Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 52.47 | |||||
Operating Margin % | 3.98 | |||||
Net Margin % | -0.44 | |||||
EBITDA Margin % | 14.88 | |||||
FCF Margin % | 0.7 | |||||
OCF Margin % | 5.18 | |||||
ROE % | -0.7 | |||||
ROA % | -0.2 | |||||
ROIC % | 2.09 | |||||
3-Year ROIIC % | 129.88 | |||||
ROC (Joel Greenblatt) % | 7.79 | |||||
ROCE % | 2.93 | |||||
Years of Profitability over Past 10-Year | 8 | |||||
Moat Score | 6 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 6.42 | |||||
PE Ratio without NRI | 6.77 | |||||
Shiller PE Ratio | 38 | |||||
Price-to-Owner-Earnings | 78.1 | |||||
PS Ratio | 0.78 | |||||
PB Ratio | 1.25 | |||||
Price-to-Free-Cash-Flow | 112.96 | |||||
Price-to-Operating-Cash-Flow | 15.11 | |||||
EV-to-EBIT | 33.54 | |||||
EV-to-Forward-EBIT | 13.38 | |||||
EV-to-EBITDA | 12.54 | |||||
EV-to-Forward-EBITDA | 12.27 | |||||
EV-to-Revenue | 1.87 | |||||
EV-to-Forward-Revenue | 1.56 | |||||
EV-to-FCF | 265.1 | |||||
Price-to-GF-Value | 0.81 | |||||
Price-to-Projected-FCF | 0.7 | |||||
Price-to-Median-PS-Value | 0.26 | |||||
Earnings Yield (Greenblatt) % | 2.98 | |||||
FCF Yield % | 0.89 | |||||
Forward Rate of Return (Yacktman) % | 5.44 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:IART
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Integra Lifesciences Holdings Corp Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 1,647.666 | ||
| EPS (TTM) ($) | -0.094 | ||
| Beta | 1.6881 | ||
| 3-Year Sharpe Ratio | -0.47 | ||
| 3-Year Sortino Ratio | -0.71 | ||
| Volatility % | 64.49 | ||
| 14-Day RSI | 44.24 | ||
| 14-Day ATR ($) | 0.707782 | ||
| 20-Day SMA ($) | 17.0895 | ||
| 12-1 Month Momentum % | 14.38 | ||
| 52-Week Range ($) | 8.7 - 20.49 | ||
| Shares Outstanding (Mil) | 77.77 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Integra Lifesciences Holdings Corp Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Integra Lifesciences Holdings Corp Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Fourth quarter earnings conference call for 2026 | 2027-02-26 08:30 | In 175 days | ||
| Annual report for 2026 | 2027-02-26 | In 174 days | ||
| Fourth quarter earnings results for 2026 | 2027-02-26 | In 174 days | ||
| Third quarter earnings conference call for 2026 | 2026-10-30 08:30 | In 56 days | ||
| Third quarter earnings results for 2026 | 2026-10-30 | In 55 days | ||
| Second quarter earnings conference call for 2026 | 2026-07-29 08:30 | 19.76 (+1.18%) | ||
| Second quarter earnings results for 2026 | 2026-07-29 | 19.76 (+1.18%) | ||
| Truist Securities MedTech Conference | 2026-06-16 15:00 | 17.46 (-3.48%) | ||
| Guidance call for 2026 | 2026-06-03 10:30 | 15.67 (-0.19%) | ||
| Guidance call for 2026 | 2026-05-12 16:20 | 13.97 (+0.58%) |
Show
Entries
Integra Lifesciences Holdings Corp Frequently Asked Questions
What is Integra Lifesciences Holdings Corp(IART)'s stock price today?
The current price of IART is $16.72. The 52 week high of IART is $20.49 and 52 week low is $8.70.
When is next earnings date of Integra Lifesciences Holdings Corp(IART)?
The next earnings date of Integra Lifesciences Holdings Corp(IART) is 2026-10-30 Est..
Does Integra Lifesciences Holdings Corp(IART) pay dividends? If so, how much?
Integra Lifesciences Holdings Corp(IART) does not pay dividend.
Guru Commentaries on NAS:IART
Invesco Small Cap Value Fund
Neutral
2025 Q1
What the manager wrote
Integra LifeSciences was mentioned as one of the fund’s health care holdings that were among the largest detractors in performance during April. However, there was no specific argument made regarding its future performance or valuation.
Press Release
Articles on Integra Lifesciences Holdings Corp
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers